Development
Traws Pharma, Inc.
TRAW
$1.50
-$0.025-1.65%
NASDAQ
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Revenue | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| SG&A Expenses | 27.60% | 3.37% | -3.34% | -2.75% | -7.84% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -9.69% | 11.73% | 47.87% | 51.61% | 40.80% |
| Operating Income | 9.79% | -11.89% | -48.52% | -52.38% | -41.38% |
| Income Before Tax | 12.21% | -5.62% | -40.10% | -44.00% | -56.33% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 12.21% | -5.62% | -40.10% | -44.00% | -56.33% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 12.21% | -5.62% | -40.10% | -44.00% | -56.33% |
| EBIT | 9.79% | -11.89% | -48.52% | -52.38% | -41.38% |
| EBITDA | 9.83% | -11.90% | -48.56% | -52.43% | -41.41% |
| EPS Basic | 12.59% | -5.25% | -39.71% | -44.05% | -19.44% |
| Normalized Basic EPS | 12.59% | -5.24% | -39.77% | -44.04% | -19.39% |
| EPS Diluted | 12.59% | -5.25% | -40.00% | -45.72% | -19.44% |
| Normalized Diluted EPS | 12.59% | -5.24% | -39.77% | -44.04% | -19.39% |
| Average Basic Shares Outstanding | 0.42% | 0.36% | 0.27% | -0.05% | 30.89% |
| Average Diluted Shares Outstanding | 0.42% | 0.36% | 0.27% | -0.05% | 30.89% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |